ELV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ELV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Elevance Health's Enterprise Value is $142,289 Mil. Elevance Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $9,079 Mil. Therefore, Elevance Health's EV-to-EBIT ratio for today is 15.67.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Elevance Health's Enterprise Value is $142,289 Mil. Elevance Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $10,693 Mil. Therefore, Elevance Health's EV-to-EBITDA ratio for today is 13.31.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Elevance Health's Enterprise Value is $142,289 Mil. Elevance Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $171,745 Mil. Therefore, Elevance Health's EV-to-Revenue ratio for today is 0.83.
The historical data trend for Elevance Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Healthcare Plans subindustry, Elevance Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Plans industry and Healthcare sector, Elevance Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Elevance Health's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Elevance Health's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 109906.96076 | + | 0 | + | 23246 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Balance Sheet Cash And Cash Equivalents |
+ | 1874 | + | 99 | - | 6526 |
= | 128,600 |
Elevance Health's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as
Enterprise Value (Q: Mar. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 121442.068 | + | 0 | + | 21976 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Balance Sheet Cash And Cash Equivalents |
+ | 4475 | + | 102 | - | 6226 |
= | 141,769 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elevance Health (NYSE:ELV) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Elevance Health's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 142288.540 | / | 9079 | |
= | 15.67 |
Elevance Health's current Enterprise Value is $142,289 Mil.
Elevance Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9,079 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Elevance Health's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 142288.540 | / | 10693 | |
= | 13.31 |
Elevance Health's current Enterprise Value is $142,289 Mil.
Elevance Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,693 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Elevance Health's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 142288.540 | / | 171745 | |
= | 0.83 |
Elevance Health's current Enterprise Value is $142,289 Mil.
Elevance Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $171,745 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Elevance Health's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Blair Williams Todt | officer: EVP and Chief Legal Officer | 8735 HENDERSON ROAD, TAMPA FL 33625 |
Ronald W Penczek | officer: SVP, Chief Accounting Officer | 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Mark Kaye | officer: EVP & CFO Designate | 7 WORLD TRADE CENTER, 250 GREENWICH ST, NEW YORK NY 10007 |
Dixon Robert L Jr | director | 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Gloria M Mccarthy | officer: EVP, Office of the CEO | WELLPOINT, INC, 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Kendrick Charles Morgan Jr | officer: EVP & President, Commercial | 220 VIRGINIA AVE, INDIANAPOLIS IN 46204 |
Deanna D Strable-soethout | director | C/O PRINCIPAL FINANCIAL GROUP, 711 HIGH ST., DES MOINES IA 50392 |
Ramiro G Peru | director | WELLPOINT, INC, 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46260 |
Peter D Haytaian | officer: EVP & Pres., Govt. Bus. Div. | 220 VIRGINIA AVE, INDIANAPOLIS IN 46204 |
Susan D. Devore | director | C/O PREMIER, INC., 13034 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Ryan M. Schneider | director | 1680 CAPITAL ONE DRIVE, MCLEAN VA 22102 |
John E Gallina | officer: SVP & Chief Accounting Officer | 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Julie A Hill | director | WELLPOINT, INC, 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Thomas C Zielinski | officer: EVP & General Counsel | |
Jeffrey D. Alter | officer: EVP, IngenioRx & Anthem Health | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
From GuruFocus
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.